Insulet's Type 2 Learning Curve Hits the Brakes on a High-Growth Story

The Beat That Wasn't

Insulet delivered a strong headline in the second quarter: total revenue grew 23% on a constant currency basis, and adjusted EPS climbed 41.5%. But the market sent the stock down ~25% in the last 90 days and it sits 58% below last September's peak. The reason: management used the call to slash the 2026 U.S. Omnipod growth outlook to 17–19% from a prior ~21–23% and openly admitted that Type 2 community retention and utilization have been disappointing.

What Actually Changed

Management had consistently told investors that type 2 attrition was in line with expectations. That script flipped. “We should have understood some of these type 2 trends sooner and done a better job of adapting our commercial and customer service model,” — Ashley McEvoy, President and Chief Executive Officer · 2026-08-05 admitted CEO Ashley McEvoy, taking the rare step of personal accountability. The company now sees a meaningfully higher dropout rate in the first 90 days, before retention stabilizes. Actions include shifting sales force compensation toward longer-term retention, scaling Omnipod Discover, and reworking the sampling program.

The Numbers Behind the Narrative

CFO Flavia Pease detailed the guidance math: about two-thirds of the cut reflects the current retention/utilization run rate, and the rest is slower year-start new customer starts and slightly lower price/mix. Crucially, the revised outlook assumes no benefit from the corrective actions. “Our updated outlook assumes current retention and utilization trends continue through the second half of the year,” — Flavia Pease, Chief Financial Officer · 2026-08-05 she said. She also gave a preliminary 2027 framework based on a mid-teens exit rate. “Our outlook does contemplate competitive entrants in 2027. However, we remain highly confident on our competitive position,” — Flavia Pease, Chief Financial Officer · 2026-08-05 she added, citing Omnipod 5 algorithm upgrades, Omnipod 6 next year, and a fully closed-loop system for type 2 in 2028.

Fundamentally, the operating model still works. Operating margin expanded 140bps year-over-year to 19.3% (adjusted), and the latest filed quarter shows GAAP operating margin at 16.0%, consistent with management's ~100bps annual expansion target.

The Contrast With Prior Confidence

Just three months earlier, on the May call, the company told analysts type 2 retention was healthy. “We are not seeing any meaningful change of year-over-year,” — Ashley McEvoy, President and Chief Executive Officer · 2026-05-06 Ashley said. CFO Flavia Pease added “the retention or attrition is exactly what we expected it would happen.” — Flavia Pease, Chief Financial Officer · 2026-05-06 Now the company is pivoting to say this is a tougher, more iterative market than type 1. The contrast is stark. Long-range growth guidance is in flux — the company will revisit its multi-year outlook on the Q4 call. The key question is whether these retention fixes are enough, or whether retention rates stabilize only for the minority who make it through the first 90 days. For now, management is betting on higher-touch onboarding and a cloud platform to lift lifetime value.

This quarter reflects both the progress we've made across our business and the important insights we've gained as we deepen our understanding of our type 2 customers.

Bottom Line

Insulet's growth engine is still strong internationally — the company actually raised the international outlook to 30–32% — but the U.S. type 2 runway now looks more expensive and longer to cultivate than investors had priced. The stock's derating reflects that. The actions are sensible, but they won't show up in revenue until late 2026 or 2027 at the earliest. The next proof point is whether the 90-day cohort metrics improve, and whether management's "execution challenge, not structural market" framing holds.